Trials / Completed
CompletedNCT04426474
A Study of LY3502970 in Participants With Type 2 Diabetes
A Multiple-Dose Study in Participants With Type 2 Diabetes Mellitus to Investigate the Safety, Tolerability, Pharmacokinetics,and Pharmacodynamics of LY3502970
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 68 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to learn more about the safety of LY3502970 and any side effects that might be associated with it. Blood tests will be done to measure how much LY3502970 is in the bloodstream, how long it takes the body to eliminate it, and how it affects blood sugar. Participation could last up to 18 weeks and may include up to 14 visits (including three overnight stays) in the study center.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3502970 | Administered orally. |
| DRUG | Placebo | Administered orally. |
Timeline
- Start date
- 2020-10-08
- Primary completion
- 2021-07-12
- Completion
- 2021-07-12
- First posted
- 2020-06-11
- Last updated
- 2021-07-27
Locations
6 sites across 2 countries: United States, Germany
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04426474. Inclusion in this directory is not an endorsement.